Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

It joins other precision medicine solutions, including the Tempus nP pharmacogenomic test and PRO™, the company’s patient reported outcome solution. "We are excited to enhance our mental ...

Q1 2025 Management View CEO Christopher Hall reported Q1 2025 revenue of $20.6 million, marking a strong start to the year.

The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

US-based Tempus has built a precision medicine platform ... and accelerating recruitment of test subjects. The two companies have been working together for some time. In January, for example ...

A massive May weekend for the Juddmonte team began perfectly on both sides of the English Channel with impressive ...

Test out Nasdaq-100® Index Options trading strategies with Options Architect. Dive into a step-by-step guide about what index options are and how you can trade them. Download the "Ultimate Guide ...

The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...

The TIME Precision Network is a newly-formed group of investigators across TIME’s provider site network dedicated to supporting Phase I trials Tempus AI, Inc. (NASDAQ: TEM), a technology company ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this.

Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...